Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

NCT02258529 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma
Small Lymphocytic Lymphoma

Interventions

DRUG: Idelalisib
BIOLOGICAL: Rituximab

Sponsor

Gilead Sciences